Recombinant Protein Manufacturing and Purification

The contract requires the production, purification, and quality control of a recombinant bovine interferon lambda Fc fusion protein manufactured under GMP or equivalent standards for use in animal studies. The work involves full-scale development and processing of the protein through expression, downstream purification, and rigorous analytical quality control to ensure purity, potency, and consistency suitable for preclinical research applications. All activities must adhere to documented procedures and regulatory expectations aligned with Good Manufacturing Practices to support the integrity of subsequent in vivo testing. The project is issued under a subcontract by the USDA ARS AFM APD with a place of performance specified in Manhattan, Kansas 66502. The solicitation was posted on July 10, 2026, with a strict response deadline of July 13, 2026, indicating urgency in securing a qualified vendor. The NAICS code 325412 identifies the industry as Pharmaceutical and Biological Product Manufacturing, underscoring the technical and regulatory sophistication required. The contractor must be capable of delivering the protein in sufficient quantity and quality to support animal studies, with full traceability and documentation for all manufacturing and testing steps.